BioSig Technologies announced the appointment of Mr. Ferdinand Groenewald to the position of interim CFO. He currently serves as Vice President, Finance at Alaunos Therapeutics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSGM:
- BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- BioSig Technologies prices 1.57M shares at $1.91 in registered direct offering
- BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders
- BioSig Technologies Bolsters Board with Strategic Appointments
- BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent